Page 1 | Search Results | Blood | American Society of Hematology

1-15 of 15

Sort by

Sort Order Select

Journal Articles

Matrix Metalloproteinase 13 (MMP13) Upregulation Is Essential for Multiple Myeloma Related Bone Lytic Lesion

Jing Fu, Ph D, Shirong Li, PhD, Rentian Feng, PhD, Huihui Ma, PhD, Farideh Sabeh, PhD, G David Roodman, MD, PhD, Markus Mapara, MD PhD, Stephen J Weiss, MD, Suzanne Lentzsch, MD, PhD

Blood (2012) 120 (21): 4025.

https://doi.org/10.1182/blood.V120.21.4025.4025

Published: 2012

Journal Articles

Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells

Jumpei Teramachi, DDS, PhD, Kyaw Ze Yar Myint, PhD, Rentian Feng, PhD, Xiangqun Xie, PhD, Jolene J. Windle, PhD, David Roodman, MD, PhD, Noriyoshi Kurihara, DDS, PhD

Blood (2011) 118 (21): 888.

https://doi.org/10.1182/blood.V118.21.888.888

Published: 2011

Journal Articles

Lenalidomide Upregulates CXCR4 on CD34 + Hematopoietic Cells Resulting In Increased Binding to Bone Marrow Niche and Inhibiting Mobilization Into Peripheral Blood In Multiple Myeloma Patients

Shirong Li, PhD, Rentian Feng, PhD, Huihui Ma, PhD, G. David Roodman, MD, PhD, Markus Y Mapara, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2010) 116 (21): 4079.

https://doi.org/10.1182/blood.V116.21.4079.4079

Published: 2010

Journal Articles

Matrix Metalloproteinses-13 (Collagenase-3) Secreted by Multiple Myeloma Cells Enhances the Bone Resorptive Activity of Osteoclasts.

Rentian Feng, PhD, Noriyoshi Kurihara, PhD, DDS, Huihui Ma, G. David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 2853.

https://doi.org/10.1182/blood.V114.22.2853.2853

Published: 2009

Journal Articles

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Rentian Feng, PhD, Xiangao Huang, PhD, Les Coulton, PhD, Hendrik De Raeve, MD, Maurizio DiLiberto, PhD, Scott Ely, MD, MPH, Guozhi Xiao, PhD, Min Luo, MD, Eline Menu, PhD, Peter Croucher, MD, G. David Roodman, MD, PhD, Karin Vanderkerken, MD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 298.

https://doi.org/10.1182/blood.V114.22.298.298

Published: 2009

Journal Articles

Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation.

Rentian Feng, PhD, Huihui Ma, Noriyoshi Kurihara, PhD, DDS, Shirong Li, PhD, Judy A Ziegler, Markus Y Mapara, MD, PhD, G. David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2009) 114 (22): 296.

https://doi.org/10.1182/blood.V114.22.296.296

Published: 2009

Journal Articles

Inhibition of Constitutively Activated JAK/STAT3 Pathway in Multiple Myeloma Cells Leads to Induction of Protective Autophagy.

Huihui Ma, M.D., Ph.D., Caisheng Lu, M.D., Ph.D., Judith Ziegler, Rentian Feng, PhD, Suzanne Lentzsch, MD, PhD, Markus Y. Mapara, MD, PhD

Blood (2009) 114 (22): 4914.

https://doi.org/10.1182/blood.V114.22.4914.4914

Published: 2009

Journal Articles

Nocodazole Induces Myeloma Cell Death by Disrupting the Microtubular Network, Resulting in G2/M Arrest

Rentian Feng, PhD, Jorge A Rios, MD, Markus Mapara, MD, PD, Suzanne Lentzsch, MD, PhD

Blood (2008) 112 (11): 3673.

https://doi.org/10.1182/blood.V112.11.3673.3673

Published: 2008

Journal Articles

Inhibition of Cdk4/6 by PD 0332991 Results in Abrogation of Osteoclast Formation

Rentian Feng, PhD, Xiangao Huang, PhD, G. David Roodman, MD, PhD, Selina Chen-Kiang, PhD, Suzanne Lentzsch, MD, PhD

Blood (2008) 112 (11): 3676.

https://doi.org/10.1182/blood.V112.11.3676.3676

Published: 2008

Journal Articles

KD7150, a Novel Mercaptoketone-Based HDAC Inhibitor, Exerts Potent Anti-Multiple Myeloma Effects In Vitro and In Vivo by Induction of DNA Damage and Mitochondrial Signaling.

Rentian Feng, PhD, Huihui Ma, PhD, Christian A. Hassig, Joseph E. Payne, Nicholas D. Smith, Markus Y. Mapara, MD, PhD, Jeffrey H. Hager, PhD, Suzanne Lentzsch, MD, PhD

Blood (2007) 110 (11): 2519.

https://doi.org/10.1182/blood.V110.11.2519.2519

Published: 2007

Journal Articles

A Novel Multiplex Drug Screening Assay for Identification of Potential Compounds with Anti-Myeloma Activity from a Library of 1120 Drugs.

Rentian Feng, PhD, Anna Lokshin, PhD, Elieser Gorelik, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 3403.

https://doi.org/10.1182/blood.V108.11.3403.3403

Published: 2006

Journal Articles

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

Rentian Feng, PhD, Gulsum Anderson, PhD, Guozhi Xiao, MD, PhD, Gary Elliott, PhD, Lorenzo M. Leoni, MD, Markus Y. Mapara, MD, PhD, David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 3456.

https://doi.org/10.1182/blood.V108.11.3456.3456

Published: 2006

Journal Articles

A Novel, Mercaptoketone-Based HDAC Inhibitor, KD5170 Exerts Marked Inhibition of Osteoclast Formation and Anti-Myeloma Activity In Vitro .

Rentian Feng, PhD, Jeffrey H. Hager, PhD, Christian A. Hassig, PhD, Shawn A. Scranton Phar, MD, Joseph E. Payne, MS, Markus Y. Mapara, MD, PhD, David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 3477.

https://doi.org/10.1182/blood.V108.11.3477.3477

Published: 2006

Journal Articles

Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo .

Rentian Feng, PhD, Ana B. Oton, MD, Kenneth Patrene, Gulsum Anderson, PhD, Markus Y. Mapara, MD, PhD, Chandra Belani, MD, David Roodman, MD, PhD, Suzanne Lentzsch, MD, PhD

Blood (2006) 108 (11): 507.

https://doi.org/10.1182/blood.V108.11.507.507

Published: 2006

Journal Articles

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth

Rentian Feng, Gülsüm Anderson, Guozhi Xiao, Gary Elliott, Lorenzo Leoni, Markus Y. Mapara, G. David Roodman, Suzanne Lentzsch

Blood (2006) 109 (5): 2130–2138.

https://doi.org/10.1182/blood-2006-07-027458

Published: 2006

Includes: Supplemental data

NARROW

Matrix Metalloproteinase 13 (MMP13) Upregulation Is Essential for Multiple Myeloma Related Bone Lytic Lesion

Blocking the ZZ Domain of Sequestosome 1/p62 Suppress the Enhancement of Myeloma Cell Growth and Osteoclast Formation by Marrow Stromal Cells

Lenalidomide Upregulates CXCR4 on CD34 + Hematopoietic Cells Resulting In Increased Binding to Bone Marrow Niche and Inhibiting Mobilization Into Peripheral Blood In Multiple Myeloma Patients

Matrix Metalloproteinses-13 (Collagenase-3) Secreted by Multiple Myeloma Cells Enhances the Bone Resorptive Activity of Osteoclasts.

Targeting CDK4/CDK6 Impairs Osteoclast Progenitor Pool Expansion and Blocks Osteolytic Lesion Development in Multiple Myeloma.

Nocodazole Induces Multiple Myeloma Cell Death and Reduces Tumor Growth through Sequential Microtubular Network Damage and C-Jun N-Terminal Kinase-Mediated Bcl-2 Phosphorylation.

Inhibition of Constitutively Activated JAK/STAT3 Pathway in Multiple Myeloma Cells Leads to Induction of Protective Autophagy.

Nocodazole Induces Myeloma Cell Death by Disrupting the Microtubular Network, Resulting in G2/M Arrest

Inhibition of Cdk4/6 by PD 0332991 Results in Abrogation of Osteoclast Formation

KD7150, a Novel Mercaptoketone-Based HDAC Inhibitor, Exerts Potent Anti-Multiple Myeloma Effects In Vitro and In Vivo by Induction of DNA Damage and Mitochondrial Signaling.

A Novel Multiplex Drug Screening Assay for Identification of Potential Compounds with Anti-Myeloma Activity from a Library of 1120 Drugs.

SDX-308, a Structural Analog of Etodolac, Inhibits NF-κB Activity Resulting in Significant Inhibition of Osteoclast Formation/Activity and Multiple Myeloma Cell Growth.

A Novel, Mercaptoketone-Based HDAC Inhibitor, KD5170 Exerts Marked Inhibition of Osteoclast Formation and Anti-Myeloma Activity In Vitro .

Combination of the Proteasome Inhibitor Bortezomib and a Histone Deacetylase Inhibitor PXD101 Results in Synergistic Inhibition of Osteoclastogenesis and Significantly Stronger Inhibition of Multiple Myeloma Growth In Vitro and In Vivo .

SDX-308, a nonsteroidal anti-inflammatory agent, inhibits NF-κB activity, resulting in strong inhibition of osteoclast formation/activity and multiple myeloma cell growth

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only